Economic Burden Can Be the Major Determining Factor Resulting in Short-Term Intermittent and Repetitive Ustekinumab Treatment for Moderate-to-Severe Psoriasis

Chong Won Choi, Ji Young Choi, Bo Ri Kim, Sang Woong Youn

Department of Dermatology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea

Background: The continuous use of biologic agents in the treatment of psoriasis has been reported to result in successful and sustained therapeutic effects and safety. However, some patients choose intermittent and repetitive treatment. Objective: To determine the factors for selecting intermittent and repetitive ustekinumab treatment for the management of psoriasis. Methods: From January 2011 to October 2016, we enrolled 30 psoriasis patients who discontinued ustekinumab treatment and were followed up for psoriasis treatment. We reviewed data regarding patients' clinical characteristics and the treatment they received, and investigated the factors for selecting intermittent treatment. Results: A total of 52 ustekinumab treatment periods were administered to the 30 patients. Of the 52 treatment periods, 34.6% were covered by insurance and 82.4% were discontinued after sufficient improvement had been made or at the patient’s request. Further analysis comparing the first and second ustekinumab treatments revealed that the patients who used ustekinumab in second treatment were more likely to be insured. In addition, the rate of patients reaching psoriasis area and severity index (PASI)75 and PASI90 was similar between the first and subsequent ustekinumab treatments. Conclusion: We found that the patients who used ustekinumab intermittently were those who were satisfied with the outcome of ustekinumab treatment but could not afford the treatment. These results suggested that economic burden can be a factor for the patients’ choice of short-term intermittent treatment. The expansion of insurance coverage can increase the effectiveness of, and patients’ satisfaction with, the management of psoriasis. (Ann Dermatol 30(2) 179~185, 2018)

Keywords—Cost of illness, Drug administration schedule, Insurance, Psoriasis, Ustekinumab

INTRODUCTION

Recent advances in the understanding of the pathogenesis of psoriasis have resulted in the introduction of new biological agents that can inhibit the action of specific molecules related to the pathogenesis of psoriasis. Ustekinumab is a human monoclonal antibody that targets the p40 subunit of interleukin (IL)-12/IL-23, thus inhibiting the IL-1/IL-17 axis in psoriasis. The long-term efficacy and safety of ustekinumab in the treatment of psoriasis are well established and long-term continuous treatment has been reported to be the most effective treatment option for ustekinumab treatment. Studies investigating the outcomes of ustekinumab treatment in real clinical practice also support the effectiveness and safety of long-term continuous ustekinumab treatment. Studies on drug survival in psoriasis treatment reported that ustekinumab had better retention
rates than anti-tumor necrosis factor agents, and the rate of adverse events was also favorable\(^6,7,9,10\). In contrast with conventional systemic agents or phototherapy, newly introduced biologic agents can be used continuously. Moreover, it has been reported that the continuous use of biologic agents results in greater and sustained therapeutic effects\(^3\). In addition, the lack of cumulative toxicity supports the continuous use of biologic agents in the treatment of psoriasis\(^3,4,11\). However, there are some patients who use biologic agents intermittently and repetitively. When choosing treatment modalities for psoriasis, the main determining factors are their effectiveness and any adverse events. However, other factors such as comorbidities, cost, and time required for treatment also influence patients’ choice.

To determine which factors lead to intermittent and repetitive ustekinumab treatment instead of long-term continuous treatment, we investigated the characteristics of psoriasis patients who were treated with ustekinumab intermittently or repetitively and described the importance of economic factors in ustekinumab treatment.

**MATERIALS AND METHODS**

**Patients and data acquisition**

We retrospectively enrolled 30 psoriasis patients who discontinued ustekinumab treatment and were followed up for psoriasis treatment. We defined the discontinuation of ustekinumab as discontinued ustekinumab treatment for more than 6 months after the last injection of ustekinumab. We defined a treatment period as the period in which the main treatment modalities are identical (Fig. 1). The 30 patients received 77 treatment periods during the study period, of which 52 were ustekinumab treatments. In addition, 8 periods of biologic agents other than ustekinumab, 7 periods of cyclosporine, 6 periods of methotrexate, 2 periods of acitretin, and 2 periods of phototherapy were included in the study. At the end of the study, 15 patients were undergoing ustekinumab treatment. This study was approved by the institutional review board of Seoul National University Bundang Hospital (IRB no. B-1603-338-102).

We collected data regarding the clinical characteristics of the patients and information on psoriasis treatment from medical records. The clinical characteristics reviewed were age, gender, body mass index, duration of psoriasis, comorbidity, biological agent naivety, age at start of ustekinumab treatment, and previous treatments for psoriasis. The data collected relating to the treatment period were psoriasis area and severity index (PASI) score at each visit, dose of ustekinumab, number of injections of ustekinumab, duration of ustekinumab treatment, method of payment for ustekinumab treatment, and reason for treatment discontinuation. Finally, to assess the effectiveness of ustekinumab treatment, we calculated the 75% and 90% reduction of PASI score from baseline (PASI75 and PASI90, respectively), as well as the time taken to achieve PASI75.

**Statistical analysis**

Statistical analysis was performed using the Mann-Whitney test and paired t-test for comparing continuous variables. Categorical variables were analyzed using the chi-square test, Fisher’s exact test and McNemar-Bowker test. Results were expressed as the mean±standard deviation and a p-value of <0.05 was considered statistically significant. Data were analyzed using IBM SPSS Statistics ver. 21.0 (IBM Co., Armonk, NY, USA).

**RESULTS**

**The characteristics of patients and ustekinumab treatment period**

Of the 77 treatment periods in the 30 psoriasis patients, the number of ustekinumab treatment periods was 52 (67.5%). Sixteen patients had ustekinumab treatment periods twice or more, with 12 patients using ustekinumab twice, three patients three times, and one patient five times. At first treatment with ustekinumab, the mean age of the patients was 43.2±9.98 years and the duration of

---

**Fig. 1. A conceptual diagram of the treatment period.** In patient A, the treatment of ustekinumab was continuous (one treatment period during the study). In patient B, four ustekinumab treatment periods during the study were observed according to severity of psoriasis. In patient C, after the discontinuation of initial ustekinumab treatment, the patient was treated intermittently and repetitively with ustekinumab or other systemic agents and phototherapy according to severity of psoriasis. In this study, we enrolled the patients who discontinued the first ustekinumab treatment and were followed up for the treatment of psoriasis such as patient B and patient C.
Table 1. Baseline demographics and characteristics of enrolled patients (n = 30)

| Characteristic          | Value                  |
|-------------------------|------------------------|
| Age (yr)                | 43.2 ± 10.0            |
| Gender                  |                        |
| Male                    | 17 (56.7)              |
| Female                  | 13 (43.3)              |
| Body mass index (kg/m²)* | 24.4 ± 4.0             |
| Co-morbidities †        |                        |
| Hypercholesterolemia    | 11 (37.9)              |
| Latent tuberculosis     | 8 (27.6)               |
| Hypertension            | 4 (13.8)               |
| Chronic hepatopathy     | 3 (10.3)               |
| Heart diseases and stroke| 1 (3.5)               |
| Diabetes                | 1 (3.5)                |
| Renal insufficiency     | 0 (0.0)                |
| Duration of psoriasis (yr) † | 18.8 ± 10.0       |
| Previous therapy        |                        |
| Topical agents          | 30 (100.0)             |
| Phototherapy            | 28 (93.3)              |
| Oral agents             | 28 (93.3)              |
| Cyclosporine            | 21 (70.0)              |
| Methotrexate            | 16 (53.3)              |
| Acitretin               | 9 (30.0)               |
| Biologic agents         | 7 (23.3)               |
| Etanercept              | 6 (20.0)               |
| Adalimumab              | 1 (3.3)                |

Values are presented as mean ± standard deviation or number (%). *Seven patients whose weights or heights were not known were omitted from the calculation. †One patient with unknown co-morbidities was omitted from the calculation. ‡One patient whose duration of psoriasis was not known was omitted from the calculation.

Psoriasis 18.8 ± 10.0 years (Table 1). Among the 30 patients, hypercholesterolemia was found in 11 (37.9%) patients and was the most common comorbidity, followed by latent tuberculosis (8 patients, 27.6%). With respect to previous therapy, 28 (93.3%) of the patients had undergone phototherapy, and 28 (93.3%) had received oral agents before the ustekinumab treatment. Twenty-three (76.7%) patients were biologics-naïve, and the remaining seven (23.3%) had experienced treatment with biologic agents, six treated with etanercept and one with adalimumab.

The mean baseline PASI score of all ustekinumab treatment periods was 12.9 ± 5.80 and the mean duration of the ustekinumab treatment periods was 13.2 ± 12.0 months (Table 2). Of the total 52 treatment periods, 18 (34.6%) were covered by insurance and 34 (65.4%) were not. Of the 34 discontinued treatment periods with known reason for withdrawal, 18 (52.9%) periods were discontinued after sufficient improvement, and 10 (29.4%) treatment periods were stopped by the patient. Five (14.7%) treatment periods were discontinued because of unsatisfactory responses or development of adverse events. One treatment period was discontinued because of the development of tongue cancer.

The outcome of the first ustekinumab treatment period and the choice of the next treatment modality

We analyzed the first ustekinumab treatment period in the 30 psoriasis patients because we speculated that the outcome of the first ustekinumab treatment period influenced the choice of subsequent treatment modalities (Table 3). The baseline mean PASI score of the first ustekinumab treatment period was 14.8 ± 5.48, which was higher than the baseline mean PASI of all 52 treatment periods (12.9 ± 5.80).

In the first ustekinumab treatment period, 6 (20.0%) treatment periods were covered by insurance, and 9 (30.0%) during the ustekinumab clinical trial. Compared to total 52 ustekinumab treatment periods, in the first ustekinumab treatment period, the proportion of treatment periods covered by insurance was low, while more patients used the ustekinumab during the clinical trial. During the first ustekinumab treatment periods, 12 (42.9%) were stopped after sufficient improvement, 10 (35.7%) at the patient's
Table 3. Characteristics of the first UST treatment period and a comparison of the patients who used UST as the second treatment and those who chose other treatments (n=30)

| Characteristic | First UST treatment (n=30) | Second treatment period with UST (n=12) | Second treatment period with agents other than UST (n=18) | p-value |
|---------------|----------------------------|----------------------------------------|------------------------------------------------------|--------|
| Age (yr)      | 43.2±10.0                  | 43.0±13.2                              | 43.3±7.5                                             | >0.999 |
| Gender        |                            |                                        |                                                      | >0.999 |
| Male          | 17 (56.7)                  | 7 (58.3)                               | 10 (55.6)                                            |        |
| Female        | 13 (43.3)                  | 5 (41.7)                               | 8 (44.4)                                             |        |
| Body mass index (kg/m²)* | 24.4±4.0              | 23.3±3.1                               | 25.3±4.5                                             | 0.483  |
| Duration of psoriasis (yr)† | 18.8±10.0             | 18.1±12.8                              | 19.2±8.0                                             | 0.777  |
| Previous therapy |                            |                                        |                                                      |        |
| Topical agents | 30 (100)                  | 12 (100)                               | 18 (100)                                             | >0.999 |
| Phototherapy  | 28 (93.3)                  | 11 (91.7)                              | 17 (94.4)                                            | >0.999 |
| Oral agents (cyclosporine, methotrexate, and acitretin) | 28 (93.3) | 10 (83.3) | 18 (100)                                             | 0.152  |
| Biologic agents | 7 (23.3)                 | 4 (33.3)                               | 3 (16.7)                                             | 0.392  |
| PASI when starting the first UST treatment‡ | 14.8±5.5              | 13.0±6.2                               | 16.2±4.7                                             | 0.135  |
| UST treatment duration (mo) | 9.3±6.4                | 8.8±6.2                                | 9.6±6.6                                              | 0.966  |
| PASI75§ | 30.7±8.8               | 28.0±7.6                               | 32.0±9.3                                             | 0.494  |
| PASI90¶ | 0.080                   |                                        |                                                      |        |

Values are presented as mean±standard deviation or number (%). UST: ustekinumab, PASI: psoriasis area and severity index. *Two patients in the UST retreatment group and 5 patients in the other than UST treatment group whose weights or heights were not known were omitted from the calculation respectively. †One patient in the non-retreatment group with duration of psoriasis not known was omitted from the calculation. ‡Two patients in the UST retreatment group and two patients in the other than UST group were omitted from the calculation respectively. §Six patients (three patients in the UST retreatment group and three patients in the non-retreatment group) were omitted from the calculation respectively. ¶Two patients (one patient in the UST retreatment group and in the other than UST group, respectively) were omitted from the calculation. Only one UST treatment was discontinued, due to occurrence of tongue cancer.

To elucidate which factors influenced the choice of ustekinumab as the second treatment modality, we divided the enrolled patients into two groups: one that used ustekinumab again, and one that was treated with agents other than ustekinumab in the second treatment period (Table 3). In the group that used ustekinumab again, 75% of the ustekinumab treatments were at the patients’ own expense, whereas in the group treated with agents other than ustekinumab, 33.3% of the treatments were at the patients’ own expense. In addition, the incidence of unsatisfactory response and adverse effects was 9.1% in the group who used ustekinumab in the second treatment, and 23.5% in the group using other agents. The analysis revealed no statistically significant differences in other demographic or treatment-related variables between the two groups.

Insurance coverage leads to choice of ustekinumab as a subsequent treatment

A total of 16 patients used ustekinumab for more than one request, and 5 (17.9%) due to unsatisfactory response or development of adverse events. After a mean of 10.7±9.08 months, the patients started another treatment period and the mean PASI score at the start of the second treatment period was 10.6±5.10. Of the 30 patients, 12 (40.0%) selected ustekinumab again, while the remaining 18 (60.0%) selected other treatment modalities: six (20.0%) chose other biologics, five (16.7%) cyclosporine, three (10.0%) methotrexate, two (6.7%) phototherapy, one (3.3%) acitretin, and one (3.3%) a topical agent only.

To elucidate which factors influenced the choice of ustekinumab as the second treatment modality, we divided the enrolled patients into two groups: one that used ustekinumab again, and one that was treated with agents other than ustekinumab in the second treatment period (Table 3). In the group that used ustekinumab again, 75% of the ustekinumab treatments were at the patients’ own expense, whereas in the group treated with agents other than ustekinumab, 33.3% of the treatments were at the patients’ own expense. In addition, the incidence of unsatisfactory response and adverse effects was 9.1% in the group who used ustekinumab in the second treatment, and 23.5% in the group using other agents. The analysis revealed no statistically significant differences in other demographic or treatment-related variables between the two groups.

Insurance coverage leads to choice of ustekinumab as a subsequent treatment

A total of 16 patients used ustekinumab for more than one
treatment period. Of these, 12 patients underwent ustekinumab treatment periods twice, three patients three times, and one patient five times. Fifteen patients were receiving ustekinumab treatment at the end of the study. When comparing between 16 patients used ustekinumab for more than one treatment period and 14 patients who used ustekinumab once, the proportion of patients with previous experience of biologic agents was higher in the patients who used ustekinumab for more than one treatment period (23.3% of patients who used ustekinumab once and 31.3% of patients used ustekinumab for more than one treatment period; \( p=0.031 \)), while the proportion of patients with previous experience of oral agents was lower compared to 14 patients who used ustekinumab once (93.3% of patients who used ustekinumab once and 87.5% of patients used ustekinumab for more than one treatment period; \( p=0.030 \)). However, the analysis revealed no statistically significant differences in other demographic variables such as age, gender, body mass index, and duration of psoriasis (data not shown). To determine which factors led to choosing ustekinumab as a subsequent treatment, we compared the first and subsequent ustekinumab treatment periods (Table 4). Between the first and subsequent ustekinumab treatment periods, the rate of reaching PASI75 and PASI90 and the time to reach PASI75 were similar. The analysis on the ways of paying for ustekinumab treatment showed that 20% of patients were covered by insurance in the first ustekinumab treatment period, but 54.5% in the subsequent ustekinumab treatment period. A further analysis on 16 patients who used ustekinumab more than one periods showed a statistically significant difference in the ways of paying for ustekinumab treatment between the first and second treatment period: the proportions of the ways of paying for first ustekinumab treatment were 6.3%, 68.8%, and 25.0% for covered by insurance, patient’s expense, and study participants, while for second ustekinumab treatment, 62.5%, 31.3%, and 6.3%, respectively (\( p=0.011 \)). In addition, there was a significant difference in the duration of ustekinumab treatment period between the first and second treatment period. The duration of first ustekinumab treatment period was \( 8.9 \pm 5.5 \), while that of second ustekinumab treatment period was \( 23.9 \pm 16.1 \) (\( p=0.004 \)).

**DISCUSSION**

Recent advances in immunologic research have increased understanding about the pathophysiology of psoriasis, and new biologic agents have been introduced for psoriasis treatment. Unlike conventional systemic agents or phototherapy, the new biologic agents can be used continuously and this was reported to result in greater and sustained therapeutic effects. In the case of ustekinumab, it was reported that continuous treatment is the most effective option for moderate-to-severe psoriasis. Continuous treatment with ustekinumab for 3 years maintained PASI75 in more than 80% of patients, whereas discontinuation of ustekinumab at 16 weeks resulted in failure to maintain PASI75 in 50% of patients. Furthermore, the lack of cumulative toxicity after the long-term treatment supports the continuous use of biologic agents in the treatment of psoriasis. However, some patients are known to discontinue biologic agents because of the relative expense of the agents, surgery, pregnancy, lactation, and low compliance with the treatment.

In this study, we enrolled a total of 30 patients who started the ustekinumab treatment but discontinued the treatment and were followed up for the treatment of psoriasis. We analyzed the treatment behaviors of these patients to reveal the factors affecting ustekinumab treatment in real clinical practice. A total of 52 ustekinumab treatment periods were documented in these 30 patients. The mean duration of an ustekinumab treatment period was \( 13.8 \pm 12.1 \) months, and 72.1% of treatment periods reached PASI75 and 34.9% reached PASI90. In this study, the effectiveness of intermittent ustekinumab treatment was slightly lower than the previously reported efficacy of continuous ustekinumab treatment. However, this result is comparable or superior to that of conventional systemic treatment modalities.

**Table 4. Comparison between the first and subsequent UST treatment periods**

|                      | First UST period (n=30) | Subsequent UST period (n=22) |
|----------------------|-------------------------|-----------------------------|
| PASI when starting each treatment period* | 14.8±5.5                | 11.0±5.7                    |
| UST treatment duration of each period (mo) | 9.3±6.4                 | 19.5±15.8                   |
| PASI75†                | 18 (75.0)               | 14 (73.7)                   |
| Time to PASI75 (wk)   | 30.67±8.8               | 27.1±5.7                    |
| PASI90†               | 8 (33.3)                | 7 (36.8)                    |
| Ways of paying for ustekinumab treatment |                      |                             |
| Covered by insurance  | 6 (20.0)                | 12 (54.5)                   |
| Patients' own expense | 15 (50.0)               | 9 (40.9)                    |
| Study participants    | 9 (30.0)                | 1 (4.5)                     |

Values are presented as mean±standard deviation or number (%). UST: ustekinumab, PASI: psoriasis area and severity index. *Four periods in first UST period group and 3 periods in subsequent UST period group were omitted from the calculation respectively. †Six periods in first UST group and 3 periods in subsequent UST group were omitted from the calculation respectively.
ities such as cyclosporine, methotrexate, and acitretin. Because intermittent use of ustekinumab showed comparable or superior effectiveness to previous systemic agents, we concluded that discontinuing ustekinumab was not due to lack of effectiveness. The analysis of the reasons for ustekinumab discontinuation confirmed our conclusion, with more than 80% of treatment periods discontinued when sufficient improvement was reached or at the patient's request. In contrast, only 14.7% discontinued the treatment period due to unsatisfactory response or adverse events. These results suggest that the intermittent treatment with ustekinumab is not due to lack of effectiveness or adverse events, but the external factors other than the effectiveness of ustekinumab.

To determine the external factors causing discontinuation of ustekinumab treatment, we performed subgroup analysis comparing between first and subsequent ustekinumab treatment. Hypothesizing that the outcomes of the first ustekinumab treatment period determined the subsequent treatment, we analyzed the first ustekinumab treatment period by comparing the patients who continued to use ustekinumab for a second period, and the patients who went on to use agents other than ustekinumab. In the analysis, we found that the proportion of treatment at their own expense was higher in the group of patients who used ustekinumab for a second treatment period, but the difference was not significant. In addition, the comparison between the first and second ustekinumab treatment periods found that the proportion of ustekinumab treatment covered by insurance in the second ustekinumab period was higher compared to that of the first ustekinumab treatment period and the duration of ustekinumab treatment was longer in the second ustekinumab treatment period. We concluded that the method of payment for ustekinumab treatment plays an important role in determining the subsequent treatment modalities and the choice of ustekinumab for subsequent treatments.

Compared to conventional systemic agents for psoriasis, newly introduced biologic agents are more expensive. Particularly in South Korea, patients with psoriasis must meet strict criteria in order to have ustekinumab treatment covered by insurance. If these conditions are not met, the patient has to undergo ustekinumab treatment at their own expense. For this reason, 65.3% of the 30 patients who underwent intermittently ustekinumab treatment were uninsured. Moreover, 75% of those who chose ustekinumab again after the first treatment underwent ustekinumab treatment at their own expense. The patients who underwent intermittent and repetitive ustekinumab treatment were satisfied with the outcome of ustekinumab treatment, but were uninsured and could not afford the economic burden of continuous treatment. This was confirmed by the findings that the effectiveness of intermittent ustekinumab treatment was comparable or superior to that of conventional systemic treatment modalities and the proportion of patients who experienced the biologic agents was higher in the patients who used ustekinumab repetitively. Moreover, it was also confirmed by that the proportion of ustekinumab treatment periods covered by insurance was significantly higher in second ustekinumab treatment periods and the duration of treatment was longer: the insurance coverage for the ustekinumab treatment resulted in using ustekinumab more actively and continuously.

Lastly, the result of this study can provide guidance for the ustekinumab treatment for psoriasis. In real clinical practice, some psoriatic patients who responded well to ustekinumab discontinue their treatment. However, there was no guidance on whether it is appropriate to resume the ustekinumab treatment in these patients. The result that the effectiveness of ustekinumab was maintained in the subsequent treatment suggests the resuming the use of ustekinumab in the patients.

This study has some limitations. Some treatments of enrolled patients were not covered by the insurance and they had to pay for ustekinumab treatment by themselves. The differences in the characteristics of the enrolled patients may have led to difference between the results of this study and those of previous clinical trials. However, considering that the insurance coverage for ustekinumab does not apply in all cases in real clinical practice, the results of this study can be a reflection of practical aspects of ustekinumab treatment.

In conclusion, we found that the patients who underwent intermittent and repetitive ustekinumab treatment discontinued their ustekinumab treatment due to the economic burden, but they chose another ustekinumab treatment intentionally. Thus, the economic burden can be the major determining factor resulting in short-term intermittent and repetitive ustekinumab treatment for moderate-to-severe psoriasis. However, in the case of psoriasis treatment with biologic agents, long-term continuous treatments have been reported to be effective and safe compared to intermittent, “as needed” treatment. Recently, the changes in the regulation for the insurance for biologic agents have reduced the burden of ustekinumab treatment in Korea, though, it is also necessary to alleviate the requirements for insurance coverage so that more psoriasis patients can use the newly introduced biologic agents. The expansion of insurance coverage for biologic agents can increase effectiveness and safety in the management of psoriasis.
ACKNOWLEDGMENT

The authors thank the Division of Statistics in the Medical Research Collaborating Center at Seoul National University Bundang Hospital for statistical analyses.

CONFLICTS OF INTEREST

The authors have nothing to disclose.

REFERENCES

1. Nickoloff BJ, Stevens SR. What have we learned in dermatology from the biologic therapies? J Am Acad Dermatol 2006;54(3 Suppl 2):S143-S151.
2. Fragoulis GE, Siebert S, McInnes IB. Therapeutic targeting of IL-17 and IL-23 cytokines in immune-mediated diseases. Annu Rev Med 2016;67:337-353.
3. Ramirez-Fort MK, Levin AA, Au SC, Gottlieb AB. Continuous versus intermittent therapy for moderate-to-severe psoriasis. Clin Exp Rheumatol 2013;31(4 Suppl 78):S63-S70.
4. Kimball AB, Gordon KB, Fakharzadeh S, Yeilding N, Szapary PO, Schenkel B, et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Br J Dermatol 2012;166:861-872.
5. Kimball AB, Papp KA, Wasfi Y, Chan D, Bissonnette R, Sofen H, et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol 2013;27:1535-1545.
6. Langley RG, Lebwohl M, Krueger GG, Szapary PO, Wasfi Y, Chan D, et al. Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up. Br J Dermatol 2015;172:1371-1383.
7. Shalom G, Cohen AD, Ziv M, Eran CB, Feldhamer I, Freud T, et al. Biologic drug survival in Israeli psoriasis patients. J Am Acad Dermatol 2017;76:662-669.e1.
8. Youn SW, Tsai TF, Cheng C, Choon SE, Wiryadi BE, Pires A, et al. The MARCOPOLO study of ustekinumab utilization and efficacy in a real-world setting: treatment of patients with plaque psoriasis in Asia-pacific countries. Ann Dermatol 2016;28:222-231.
9. Puig L, Ruiz-Salas V. Long-term efficacy, safety and drug survival of ustekinumab in a Spanish cohort of patients with moderate to severe plaque psoriasis. Dermatology 2015;230:46-54.
10. Vergou T, Moustou AE, Antoniou C. Five-year experience with Ustekinumab for psoriasis: real-life data of a single centre. J Eur Acad Dermatol Venereol 2017;31:e40-e41.
11. Gordon KB, Langley RG, Leonardi C, Toth D, Menter MA, Kang S, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006;55:598-606.
12. Yeung H, Wan J, Van Voorhees AS, Callis Duffin K, Krueger GG, Kalb RE, et al. Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis. J Am Acad Dermatol 2013;68:64-72.
13. Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009;61:451-485.
14. Staidle JP, Dabade TS, Feldman SR. A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency. Expert Opin Pharmacother 2011;12:2041-2054.
15. Gordon KB, Gottlieb AB, Leonardi CL, Elewski BE, Wang A, Jahreis A, et al. Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy. J Dermatolog Treat 2006;17:9-17.
16. Papp K, Crowley J, Ortonne JP, Leu J, Okun M, Gupta SR, et al. Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy. Br J Dermatol 2011;164:434-441.